Tasly Pharmaceutical Group Co., Ltd (SHA: 600535)
China flag China · Delayed Price · Currency is CNY
15.59
-0.13 (-0.83%)
Nov 13, 2024, 3:00 PM CST

Tasly Pharmaceutical Group Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2014
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Operating Revenue
8,5278,6368,6067,89813,50518,932
Upgrade
Other Revenue
37.7137.7131.1953.8670.8265.83
Upgrade
Revenue
8,5658,6748,6377,95213,57618,998
Upgrade
Revenue Growth (YoY)
-5.63%0.42%8.62%-41.43%-28.54%5.61%
Upgrade
Cost of Revenue
2,8522,8853,1472,6828,11513,056
Upgrade
Gross Profit
5,7135,7895,4905,2695,4615,943
Upgrade
Selling, General & Admin
3,3213,3263,2673,3393,2153,405
Upgrade
Research & Development
923.72917.27845.34579.53689.33551.22
Upgrade
Other Operating Expenses
100.0897.6237.96110.64104.05139.29
Upgrade
Operating Expenses
4,3494,3494,1494,0274,0734,095
Upgrade
Operating Income
1,3631,4401,3411,2431,3881,848
Upgrade
Interest Expense
-75.6-82.52-64.86-77.39-286.69-451.08
Upgrade
Interest & Investment Income
106.07107.55107.551,792241.0433.51
Upgrade
Currency Exchange Gain (Loss)
-1.23-1.23-1.617.275.58-5.3
Upgrade
Other Non Operating Income (Expenses)
-1.41-4.73-71.110-11.05-12.06
Upgrade
EBT Excluding Unusual Items
1,3911,4591,3112,9651,3371,413
Upgrade
Impairment of Goodwill
---151.2--59.01-33.03
Upgrade
Gain (Loss) on Sale of Investments
-380.99-282.81-1,125-79.88118.21-169.77
Upgrade
Gain (Loss) on Sale of Assets
-1.3-1.63-4.9341.27-5.67-1.34
Upgrade
Asset Writedown
-41.86--194.64-262.53--19.18
Upgrade
Other Unusual Items
46.6746.67-1.9660.0466.91141.21
Upgrade
Pretax Income
1,0141,221-167.632,7241,4571,331
Upgrade
Income Tax Expense
169.11204.46180.82315.92367.2327.63
Upgrade
Earnings From Continuing Operations
844.681,017-348.462,4081,0901,003
Upgrade
Minority Interest in Earnings
36.3854.4384.22-48.7536.03-1.74
Upgrade
Net Income
881.051,071-264.242,3591,1261,001
Upgrade
Net Income to Common
881.051,071-264.242,3591,1261,001
Upgrade
Net Income Growth
-20.77%--109.51%12.43%-35.19%
Upgrade
Shares Outstanding (Basic)
1,5001,4941,4681,5021,5011,517
Upgrade
Shares Outstanding (Diluted)
1,5001,4941,4681,5021,5011,517
Upgrade
Shares Change (YoY)
2.18%1.77%-2.29%0.08%-1.06%0.16%
Upgrade
EPS (Basic)
0.590.72-0.181.570.750.66
Upgrade
EPS (Diluted)
0.590.72-0.181.570.750.66
Upgrade
EPS Growth
-22.47%--109.33%13.64%-35.29%
Upgrade
Free Cash Flow
2,0331,9071,8752,2291,382949.37
Upgrade
Free Cash Flow Per Share
1.361.281.281.480.920.63
Upgrade
Dividend Per Share
0.5900.3300.3300.3300.3300.330
Upgrade
Dividend Growth
78.79%0%0%0%0%10.00%
Upgrade
Gross Margin
66.70%66.74%63.56%66.27%40.23%31.28%
Upgrade
Operating Margin
15.92%16.60%15.52%15.63%10.22%9.73%
Upgrade
Profit Margin
10.29%12.35%-3.06%29.66%8.29%5.27%
Upgrade
Free Cash Flow Margin
23.74%21.98%21.71%28.04%10.18%5.00%
Upgrade
EBITDA
1,7591,8521,7741,6481,9272,235
Upgrade
EBITDA Margin
20.54%21.35%20.54%20.72%14.20%11.76%
Upgrade
D&A For EBITDA
395.93412.21433.92405.08539.67386.72
Upgrade
EBIT
1,3631,4401,3411,2431,3881,848
Upgrade
EBIT Margin
15.92%16.60%15.52%15.63%10.22%9.73%
Upgrade
Effective Tax Rate
16.68%16.74%-11.60%25.20%24.62%
Upgrade
Revenue as Reported
8,5658,6748,637-13,57618,998
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.